Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin

Bibliographic Details
Main Authors:	Farr, Amanda M, Sheehan, John J, Davis, Brian M, Smith, David M
Format:	Online
Language:	English
Published:	Dove Medical Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979597/

Similar Items

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
by: Farr, Amanda M., et al.
Published: (2014)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
by: Messori, Andrea, et al.
Published: (2014)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
by: Vaidya, Varun, et al.
Published: (2016)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble, Michael E, et al.
Published: (2012)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
by: Minze, Molly G., et al.
Published: (2013)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
by: Retlich, Silke, et al.
Published: (2015)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: Saine, M Elle, et al.
Published: (2015)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
by: Freeman, Jeffrey S
Published: (2013)

Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
by: Farr, Amanda M., et al.
Published: (2016)

Clinical utility and tolerability of linagliptin in diabetic patients
by: Maxwell, Lauralee Gordon, et al.
Published: (2013)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley, Richard E
Published: (2014)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
by: Dave, Darshan J.
Published: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
by: Shubrook, Jay, et al.
Published: (2011)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar, Chetan S, et al.
Published: (2013)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
by: Iqbal, Nayyar, et al.
Published: (2014)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
by: Ott, Christian, et al.
Published: (2014)

Linagliptin: from bench to bedside
by: Doupis, John
Published: (2014)

The clinical application of linagliptin in Asians
by: Cao, Chu-qing, et al.
Published: (2015)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
by: Elgart, Jorge F, et al.
Published: (2013)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
by: Panagoulias, George S, et al.
Published: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
by: Perl, Shira, et al.
Published: (2016)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
by: Jain, Rajeev
Published: (2015)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
by: Neumiller, Joshua J.
Published: (2014)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
by: Konya, Hiroyuki, et al.
Published: (2014)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
by: Rauch, Thomas, et al.
Published: (2012)

Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus
by: Jermendy, György, et al.
Published: (2012)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
by: Jadhav, Sushant B., et al.
Published: (2016)

Incorrect description of mode of excretion of linagliptin
by: Woerle, Hans-Juergen, et al.
Published: (2010)

Acute Kidney Injury Associated with Linagliptin
by: Nandikanti, Deepak K., et al.
Published: (2016)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
by: Gallwitz, Baptist
Published: (2012)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
by: Gallwitz, Baptist
Published: (2013)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
by: von Websky, Karoline, et al.
Published: (2013)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
by: Guedes, Erika Paniago, et al.
Published: (2013)

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
by: Annayya R. Aroor, et al.
Published: (2018-04-01)

Linagliptin alleviates fatty liver disease in diabetic db/db mice
by: Michurina, Svetlana V, et al.
Published: (2016)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
by: Dietrich, Nadine, et al.
Published: (2016)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
by: Haak, Thomas
Published: (2015)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich, Robert, et al.
Published: (2012)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
by: Darsalia, Vladimer, et al.
Published: (2013)